News

The move doubles the CRO’s capacity in Europe.

The companies agree to jointly develop and promote MOR202, an oncology mAb in a deal potentially valued at more than $800 million.

Programs assist in the fast track of drugs for serious conditions.

Companies hope the collaboration will result in identifying potential new drug candidates using fewer rounds of design, synthesis, and testing.

A study shows significant improvement in public perceptions of clinical trial safety, trust in the motives of research professionals, and appreciation for trial volunteers.

Waters Corporation introduced the Waters SYNAPT G2-Si Mass Spectrometer, which integrates a third dimension of resolution and separation power.

Agilent Technologies Inc. introduced the MassHunter BioConfirm application, which allows users to rapidly create targeted screening methods.

Bruker Chemical and Applied Markets offers three LC-triple quadrupole (LC-TQ) mass spectrometers, the EVOQ Qube, the EVOQ Elite, and the EVOQ Elite ER.

The US Food and Drug Administration took action against more than 9,600 websites that illegally sell potentially dangerous, unapproved prescription medicines to consumers.

Serelaxin, to treat acute heart failure, is the second Novartis drug to get new designation from FDA.

The EMA's Committee for Medicinal Products for Human Use has recommended granting of marketing authorizations for the first two monoclonal antibody biosimilars.

The Alliance for Fair Trade with India is seeking action to resolve discriminatory trade practices and improved protection of intellectual property rights.

Global program seeks to confirm biosimilarity to support regulatory submissions in the US and EU.

NIH awards $12.7 million for collaborations between nine academic research groups and pharmaceutical industry partners to explore new treatments.

The billion-dollar deal strengthens J&J's oncology portfolio.

The settlement comes after a nearly 10-year legal battle in which Pfizer and Nycomed (now part of Takeda) sought to enforce the patent for its blockbuster acid reflux medicine.

Semi-automatic technology aids egg-based influenza vaccine production in smaller facility footprints.

The Developability Assessment Platform evaluates manufacturability and safety in discovery and early-stage biological drug development.

The multimillion investment in a facility in Cambridge is part of the company’s move to create strategic global R&D centers in the UK, US and Sweden.

A proposed deal with Aspen includes the company’s site in Notre-Dame-de-Bondeville, France.

The move follows rejection of Elan shareholders of certain key deals and withdrawal of Royalty Pharma bid.

Cobra Biologics announced several product development projects with Novolytics, Recopharma, and Vaccibody.

The US Supreme Court ruled that naturally occurring isolated biological material is not patentable, but a synthetic version of gene material may be patented.

ISPE study reveals quality systems of manufacturing as the leading cause of drug shortages.

EMA?s revised guideline on biosimilars containing biotechnology-derived proteins is published for public consultation.

One employee is dismissed, another has resigned, and three others are put on administrative leave.

The multimillion deal focuses on oncology.

Elan urges its shareholders to reject bid in an upcoming meeting on June 17.